Actinium Pharmaceuticals

Update in progress

ATNM (NYSE American)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Actinium Pharmaceuticals develops antibody–radiation conjugates and targeted radiotherapies to improve outcomes after failed cancer treatments. Lead assets include Actimab-A (CD33 radiotherapeutic for Relapsed/Refractory AML, in Phase 2/3), Iomab-ACT to enable cellular therapies like CAR-T, ATNM-400 (alpha emitter for prostate cancer), and Iomab-B for conditioning before bone marrow transplant. Also collaborates with the NCI on Actimab-A and pursues preclinical programs for solid tumors. Based in New York.

Company score

Sentiment: 0.36; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.08; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive